Biomolecules & Therapeutics : eISSN 2005-4483 / pISSN 1976-9148

Download original image
Fig. 1. Resorcinol inhibits B[a]P effects on both XRE-mediated signaling and cell survival in HaCaT cells. (A) Chemical structure of resorcinol. (B) HaCaT cells were transfected with the XRE-Luc reporter together with a Renilla-luciferase vector using the DharmaFECT® Duo transfection reagent (Thermo Fischer Scientific, Waltham, MA, USA). After incubation for 24 h, the cells were treated with resorcinol in the presence of B[a]P under serum-free conditions for 14 h. These cells were then harvested and subjected to a luciferase activity assay. *p<0.05 vs. B[a]P-treated control. Three biological experimental replicates were performed. Data are expressed as mean ± SD. (C, D) HaCaT cells were incubated with resorcinol in the presence of B[a]P (15 μM) for 24 h, and western blot analysis (C) and real-time PCR analysis (D) for CYP1A1 were performed. Three biological experimental replicates were performed. Data are expressed as mean ± SD. *p<0.05 vs. B[a]P-treated control. (E) HaCaT cells were incubated with resorcinol (3 mM) in the presence of B[a]P (15 μM) for 24 h, and Western blot analysis was performed for AhR. Three biological experimental replicates were performed. (F) HaCaT cells were incubated with resorcinol (3 mM) in the presence of B[a]P (15 μM) for 48 h, and cell survival assay was performed. Three biological experimental replicates were performed. Data are expressed as mean ± SD. *p<0.05 vs. untreated control, °p<0.05 vs. B[a]P-treated control. RES: resorcinol.
Biomolecules & Therapeutics 2021;29:227~233 https://doi.org/10.4062/biomolther.2020.083
© Biomolecules & Therapeutics